How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

Video Library —July 18, 2018
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Chief of Medical Oncology
Director, Thoracic Oncology Research Program Associate Director for Translational
Research Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
David L Rimm, MD, PhD
Professor of Pathology and Medicine (Oncology)
Yale University School of Medicine
New Haven, CT
Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.
Related Articles
Dealing with Multidrug Combination Therapy for Multiple Myeloma
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, describe their approach to advising patients on combination therapy, especially with multidrug regimens, and counseling them on treatments that may be needed to prevent or treat therapy-related adverse events.
Best Practices in Counseling Multiple Myeloma Patients on Therapeutic Options
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, provide their perspectives on how to counsel patients on the best frontline treatment options for newly-diagnosed MM, and how this differs from relapsed/refractory MM, where individualizing treatment plans based on the patient needs and tolerability of treatment is key.
Landscape Shifts in Treating Multiple Myeloma
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, enumerate the major landscape shifts over the past 5 years in treating MM, including an increasing number of treatment options, the emergence of MRD testing to guide therapy, the availability of clinical trials, and the deeper, more durable responses new agents provide.
Last modified: August 30, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code